Adding Lifileucel to Pembrolizumab for Immunotherapy-Naïve Melanoma Improved Responses


A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.

Pembrolizumab (Keytruda) combined with lifileucel (LN-144) led to a high overall response rate (ORR) for patients with immune checkpoint inhibitor (ICI)–naïve advanced melanoma in a phase 2 trial, according to a presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

“Advanced melanoma remains a significant health burden with a high unmet clinical need despite treatment advances in immunotherapy,” Sajeve Samuel Thomas, MD, lead study author and medical oncologist and hematologist at Orlando Health Cancer Institute in Florida, said during the meeting. “Lifileucel TIL [tumor-infiltrating lymphocyte]-cell therapy has demonstrated efficacy and durability of response in patients with advanced metastatic melanoma who have progressed while on or following treatment with anti–PD-1 or PD-L1 therapy.”

Investigators on the multicenter, multi-cohort, open-label study (IOV-COM-202; NCT03645928) enrolled 7 patients with ICI-naïve advanced melanoma (unresectable or metastatic) as of February 14, 2021. Five of the 7 patients were treatment-naïve whereas 1 patient each received prior treatment with BRAF and MEK inhibitors and prior chemotherapy.

In addition, 71% of patients had liver/brain lesions and 43% had lactate dehydrogenase levels greater than the upper limit of normal. The mean target lesion sum of diameter was 111.4 mm, with 85.7% of patients having a more than 3 target and non-target lesions, “representing advanced disease at baseline for this patient group,” Thomas said. “The primary efficacy endpoint was investigator-assessed objective response rate using RECIST version 1.1, while the primary safety endpoint measured the incidence of grade 3 or higher treatment-emergent adverse events.”

Lifileucel is generated at centralized good manufacturing practice facilities during a 22-day process. Researchers administered a nonmyeloablative lymphodepletion using cyclophosphamide and fludarabine before a single infusion of lifileucel. This was followed by no more than 6 doses of lifileucel at 600,000 IU/kg.

Patients were followed-up for a median of 8.2 months, and the mean number of TIL cells infused into patients was 27.3 billion.

Six patients had a confirmed objective response with an overall response rate (ORR) of 86%. In particular, 1 patient had a complete response and 5 patients had a partial response. Three patients who originally responded to therapy were no longer taking pembrolizumab due to adverse events at 3 months, 4 months, and 13 months, although they continue to have a maintained response.

Of note, the longest duration of response was 16.8 months. The complete response rate was 42.9%.

Treatment-related adverse events occurred in at least 30% of patients in the study and included thrombocytopenia, chills, nausea, pyrexia, vomiting, fatigue, febrile neutropenia, hypertension, neutropenia, alopecia, cough, decreased appetite and peripheral edema. This adverse event profile was consistent with the underlying disease and the known adverse effect profiles of nonmyeloablative lymphodepletion, pembrolizumab and lifileucel. There were no grade 5 treatment-emergent adverse events during this study, and unexpected toxicity was seen in patients related to pembrolizumab after TIL therapy.

“We are encouraged by this data confirming the potential feasibility and activity of combination lifileucel and pembrolizumab in the early-line treatment of patients with advanced metastatic melanoma,” Thomas concluded.

Of note, enrollment into the IOV-COM-202 trial is ongoing.


Thomas SS, In KG, Doger B, et all. Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma. J Clin Oncol. 2021;39(suppl 15):9537.

Related Videos
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content